Literature DB >> 30830284

Dorsal root ganglia volume is increased in patients with the Fabry-related GLA variant p.D313Y.

Tim Godel1, Philipp Bäumer2,3, Katharina Stumpfe4, Nicole Muschol4, Moritz Kronlage2, Merle Brunnée2, Jennifer Kollmer2, Sabine Heiland2, Martin Bendszus2, Victor-Felix Mautner5.   

Abstract

PURPOSE: To examine dorsal root ganglia and proximal nerve segments in patients carrying the Fabry-related GLA-gene variant p.D313Y in comparison to patients with classical Fabry mutations and healthy controls by morphometric and functional magnetic resonance neurography.
METHODS: This prospective multicenter study examines the lumbosacral dorsal root ganglia and sciatic nerve in 11 female p.D313Y patients by a standardized magnetic resonance neurography protocol at 3 T. Volumes of dorsal root ganglia L3 to S2, permeability of dorsal root ganglia L5 and S1, and spinal nerve L5 as well as cross-sectional area of the sciatic nerve were assessed and compared to 10 females carrying a classical Fabry mutation and 16 healthy female controls.
RESULTS: Compared to healthy controls, dorsal root ganglia volumes of p.D313Y females were enlarged by 53% (L3), 48% (L4), 43% (L5), 57% (S1) (p < 0.001), and 55% (S2) (p < 0.05), but less pronounced compared to females carrying a classical Fabry mutation. Compared to healthy controls, p.D313Y patients showed no changes of dorsal root ganglia vascular permeability, while patients with a classical Fabry mutation showed a distinct decrease (p < 0.05). Sciatic nerve cross-sectional area was mildly increased by 6% in p.D313Y as well as in classical Fabry patients (p < 0.05).
CONCLUSIONS: Patients carrying the GLA-gene variant p.D313Y show distinctly enlarged dorsal root ganglia, while vascular permeability remains within normal limits. Overall, these alterations partially share characteristics commonly seen in patients with a mutation causing classical FD. This suggests that p.D313Y causes a potentially treatable condition resembling an early stage of Fabry disease.

Entities:  

Keywords:  Dorsal root ganglia; Fabry disease; Magnetic resonance neurography; Neuropathic pain; Peripheral neuropathy

Mesh:

Substances:

Year:  2019        PMID: 30830284     DOI: 10.1007/s00415-019-09262-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

1.  Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease.

Authors:  Markus Niemann; Arndt Rolfs; Anne Giese; Hermann Mascher; Frank Breunig; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  JIMD Rep       Date:  2012-07-01

2.  Dorsal root ganglia in vivo morphometry and perfusion in female patients with Fabry disease.

Authors:  Tim Godel; Anja Köhn; Nicole Muschol; Moritz Kronlage; Daniel Schwarz; Jennifer Kollmer; Sabine Heiland; Martin Bendszus; Victor-Felix Mautner; Philipp Bäumer
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

3.  The mutation p.D313Y is associated with organ manifestation in Fabry disease.

Authors:  M du Moulin; A F Koehn; A Golsari; S Dulz; Y Atiskova; M Patten; J Münch; M Avanesov; K Ullrich; N Muschol
Journal:  Clin Genet       Date:  2017-04-24       Impact factor: 4.438

4.  Human dorsal root ganglion in vivo morphometry and perfusion in Fabry painful neuropathy.

Authors:  Tim Godel; Philipp Bäumer; Mirko Pham; Anja Köhn; Nicole Muschol; Moritz Kronlage; Jennifer Kollmer; Sabine Heiland; Martin Bendszus; Victor-Felix Mautner
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

5.  The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.

Authors:  Lis Hasholt; Martin Ballegaard; Henning Bundgaard; Michael Christiansen; Ian Law; Allan M Lund; Anne Norremolle; Ase Krogh Rasmussen; Kirstine Ravn; Zeynep Tumer; Flemming Wibrand; Ulla Feldt-Rasmussen
Journal:  Scand J Clin Lab Invest       Date:  2017-10-16       Impact factor: 1.713

6.  Involvement of dorsal root ganglia in Fabry's disease.

Authors:  N Gadoth; U Sandbank
Journal:  J Med Genet       Date:  1983-08       Impact factor: 6.318

7.  Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.

Authors:  C M Eng; L A Resnick-Silverman; D J Niehaus; K H Astrin; R J Desnick
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

8.  Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.

Authors:  Makiko Yasuda; Junaid Shabbeer; Stacy D Benson; Irene Maire; Roger M Burnett; Robert J Desnick
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

Review 9.  Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Authors:  Christine M Eng; Dominique P Germain; Maryam Banikazemi; David G Warnock; Christoph Wanner; Robert J Hopkin; Jan Bultas; Philip Lee; Katherine Sims; Scott E Brodie; Gregory M Pastores; Joerg M Strotmann; William R Wilcox
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

10.  Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.

Authors:  Daniel Oder; Nurcan Üçeyler; Dan Liu; Kai Hu; Bernhard Petritsch; Claudia Sommer; Georg Ertl; Christoph Wanner; Peter Nordbeck
Journal:  BMJ Open       Date:  2016-04-08       Impact factor: 2.692

View more
  2 in total

1.  Bridging the Gap Between Vessels and Nerves in Fabry Disease.

Authors:  Julia Forstenpointner; Manon Sendel; Paul Moeller; Maren Reimer; Sima Canaan-Kühl; Jens Gaedeke; Stefanie Rehm; Philipp Hüllemann; Janne Gierthmühlen; Ralf Baron
Journal:  Front Neurosci       Date:  2020-06-16       Impact factor: 4.677

2.  Dorsal Root Ganglia Volume-Normative Values, Correlation with Demographic Determinants and Reliability of Three Different Methods of Volumetry.

Authors:  Moritz Kronlage; Thomas David Fischer; Rouven Behnisch; Daniel Schwarz; Philipp Bäumer; Veronique Schwehr; Sabine Heiland; Martin Bendszus; Tim Godel
Journal:  Diagnostics (Basel)       Date:  2022-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.